10-Q: Calidi Biotherapeutics Faces Going Concern Doubt Amidst Restructuring

Calidi Biotherapeutics reports significant net losses and accumulated deficit, raising substantial doubt about its ability to continue as a going concern, prompting a 67% workforce reduction.

Summary

• Calidi Biotherapeutics, Inc. filed a Form 10-Q for the quarterly period ended September 30, 2026.
• The company reported a net loss of $3.646 million for the three months ended September 30, 2026, and $11.914 million for the nine months ended September 30, 2026.
• As of September 30, 2026, the company had an accumulated deficit of $153.5 million.
• There is substantial doubt about the company's ability to continue as a going concern within 12 months from the issuance date of the financial statements.
• The company implemented a restructuring plan on November 6, 2026, reducing headcount by approximately 67% to cut costs and extend its operating runway.
• The company is actively pursuing additional financing to meet its operating and capital requirements.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued net losses, substantial accumulated deficit, and the explicit statement of substantial doubt about its ability to continue as a going concern, despite efforts to reduce costs and pursue financing.

Positives

• Research and development expenses decreased by $1.045 million for the three months ended September 30, 2026, compared to the same period in 2025, primarily due to a reduction in headcount and associated salaries and benefits.
• General and administrative expenses decreased by $3.561 million for the nine months ended September 30, 2026, compared to the same period in 2025, largely due to reduced headcount and associated costs.
• The company received a $0.6 million research allowance refund for its German subsidiary, StemVac.
• The company entered into a new lease agreement for office and laboratory space, and terminated its previous lease with no early termination fee.
• The company received Fast Track Designation from the FDA for its SuperNova investigational drug candidate (CLD-201) for the treatment of soft tissue sarcoma.

Negatives

• The company reported a net loss of $3.646 million for the three months ended September 30, 2026, and $11.914 million for the nine months ended September 30, 2026.
• The company has an accumulated deficit of $153.5 million as of September 30, 2026.
• There is substantial doubt about the company's ability to continue as a going concern within the next 12 months.
• The company's cash balance of $3.9 million and restricted cash of $0.2 million as of September 30, 2026, are insufficient to cover projected expenses for the next year.
• The company received a notice from NYSE American LLC for non-compliance with the stockholders' equity continued listing standard.
• The company is subject to ongoing litigation, including claims of defamation, constructive discharge, and securities fraud.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital through public or private equity or debt financings.
• If the company issues equity securities to raise funds, existing stockholders may experience dilution.
• The company may not be able to secure necessary financing in a timely manner or on favorable terms.
• The company is subject to ongoing litigation, including claims of defamation, constructive discharge, and securities fraud, which could result in significant financial and operational impacts.
• The company faces risks associated with the development of its product candidates, including the uncertainty of clinical trial outcomes, regulatory approvals, and commercialization.
• The company's common stock is subject to delisting proceedings by NYSE American LLC if it does not regain compliance with continued listing standards.

Future Outlook

The company expects to continue incurring significant expenses and operating losses in the foreseeable future as it advances its product candidates through development, seeks regulatory approval, and operates as a public company. Substantial additional funding is required to support operations and growth strategies, with a significant risk of not being able to secure such funding on acceptable terms. The company anticipates entering the clinic in the second half of 2027 with CLD-401.

Management Comments

• The company is pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease.
• The RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites.
• The company expects to enter the clinic in the second half of 2027 with CLD-401, the first compound from the RedTail platform.
• The company will need substantial additional funding to support its continuing operations and pursue its growth strategy.
• The company has concluded that its current liquidity resources raise substantial doubt about its ability to continue as a going concern within 12 months.

Industry Context

StockSavvy.ai notes that Calidi Biotherapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on oncolytic virus therapies. The company's RedTail platform aims to overcome a key industry challenge: systemic delivery of oncolytic viruses to metastatic sites, a hurdle that has limited previous approaches. The company's strategy to develop multiple product candidates from this platform, including CLD-401, CLD-501, and CLD-502, aligns with industry trends of developing targeted therapies with enhanced immune-modulating capabilities.

Comparison to Industry Standards

• The company's net loss of $11.9 million for the nine months ended September 30, 2026, and accumulated deficit of $153.5 million are significant for a clinical-stage biotechnology company, reflecting the high costs of drug development.
• The company's cash burn rate, as indicated by the $10.8 million used in operating activities for the nine months ended September 30, 2026, is substantial, necessitating continuous fundraising efforts common in the biotech industry.
• The company's reliance on equity financings, including public offerings and at-the-market programs, is a standard practice for early-stage biotechs to fund operations and development pipelines.
• The company's pursuit of Fast Track Designation for CLD-201 is a strategic move to expedite the development and review process, a common goal for companies with promising drug candidates in areas of unmet medical need.

Corporate Governance

Legal Proceedings

• Consolidated legal proceedings involving former employees (Tony Kalajian, Hazel Sanchez) alleging defamation, constructive discharge, and related claims, with a trial date set for May 14, 2027.
• Lawsuit filed by a former executive assistant alleging breach of fiduciary duty, conversion, and misappropriation of confidential information, with a trial scheduled for May 21, 2027.
• Securities fraud lawsuit filed by Yian Zeng (Zeng Federal Case) and a related state court action alleging similar claims, with a motion for summary judgment pending.
• The company is vigorously defending itself against all legal claims and denies all allegations.

Related Party Transactions

• Director F provided a personal guaranty for a lease, with a related Guaranty Note that was partially settled and fully paid off by September 30, 2026.
• Officer G and Officer A received severance payments and related benefits, which were settled in full by September 30, 2026.
• Company A, related to Director G, provided CRO services, with outstanding amounts settled by September 30, 2026.
• The company's former CEO and former chairman of the Board of Directors were involved in past investments.

Stakeholder Impact

• Shareholders may experience dilution due to future equity financings required to sustain operations.
• The company's ongoing financial struggles and potential delisting from NYSE American could negatively impact shareholder value.
• Employees are impacted by the restructuring plan, which involves a 67% reduction in headcount.
• Creditors and suppliers may face risks if the company is unable to secure necessary financing, potentially impacting payment timelines.

Next Steps

• Continue advancing current and future product candidates through preclinical and clinical development.
• Seek regulatory approval for product candidates.
• Pursue additional financing to meet operating and capital requirements.
• Complete the restructuring plan, which is expected to be substantially completed during the fourth quarter of 2026.
• Evaluate strategic alternatives to maximize stockholder value, including potential merger, acquisition, or other strategic transactions.
• Regain compliance with NYSE American LLC's continued listing standards by March 21, 2028, as per the submitted plan.

Key Dates

Recommendation

The company's severe financial distress, evidenced by substantial doubt about its going concern status, significant accumulated deficit, ongoing net losses, and a major workforce reduction, presents a high-risk investment profile. Despite ongoing research and development efforts, the immediate need for substantial capital raises, coupled with potential delisting from NYSE American and ongoing litigation, outweighs the speculative potential of its drug pipeline in the short to medium term.

Keywords

biotechnology, oncolytic virus, genetic medicine, drug development, clinical trials, RedTail platform, CLD-401, regenerative medicine